By Marie Rosenthal
A head-to-head comparison of two antiplatelet therapies found that a lower dose of prasugrel was as effective as a standard dose of ticagrelor (Brilinta, AstraZeneca) for geriatric or low-weight patients with acute coronary syndromes (ACS), and was also associated with a reduced risk for bleeding.
Dual antiplatelet therapy, mostly clopidogrel and aspirin, has been the mainstay of treatment for ACS. Two large randomized trials showed that when added to aspirin, the P2Y12